Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Maia – page 19

691 clinical trials in Maia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Maia at a glance
691
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

691 trials in Maia

Open in trial search

B-cell lymphoma+1

Recruiting

Study of Pembrolizumab for Children with Advanced Melanoma or PD-L1 Positive Solid Tumors and Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on the Safety and Effects of UX701 Gene Therapy for Adults with Wilson Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Eculizumab
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Asthma

Recruiting

Study on the Effectiveness and Safety of Indacaterol Acetate/Mometasone Furoate vs. Budesonide for Children Aged 6-11 with Asthma

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:Novartis Pharma AG

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Protein C
  • Sponsor:Takeda Development Center Americas Inc.

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BMS-986515
  • Sponsor:Celgene Corp.

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Migraine+2

Recruiting

Study on Long-term Safety and Tolerability of Atogepant for Children and Teens (Ages 6-17) with Migraine

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Belumosudil Mesilate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Maia

What the registry says about research in the country

01 Cardiovascular Research

Ongoing clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. Research aims to evaluate innovative treatment approaches for reducing inflammatory markers in dialysis patients.

  • Cardiovascular outcomes in ESKD patients
  • Inflammatory biomarker reduction
  • Dialysis patient care optimization

These studies investigate the relationship between inflammatory markers and cardiovascular health in patients undergoing maintenance dialysis, potentially leading to improved treatment strategies for this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.